Doctor profile · Federal record
Dr. Greg Mott, M.D.
Internal Medicine Physician (CMS: Rheumatology) · Cincinnati, OH
- NPI 1093101750
- Accepts Medicare
- MIPS 91.2 / 100 · 2023
- 11 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
234 Goodman St., Ml 0781
Cincinnati, OH 45219
(513) 584-4505
fax (513) 584-0468
Credentials & registration
- NPI registered
- April 2015 — 11 yrs on file
- Profile last updated
- April 10, 2017
- Year of graduation
- 2015 — 11 yrs since
- Specialty taxonomy
- 207R00000X — NUCC code
- State license (1)
- Ohio #57.026515
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1093101750. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
13,515
Distinct HCPCS
10
Medicare allowed
$534,132
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J0129 |
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 5,000 | 14 | $42 | |
Q5104 |
Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 4,097 | 21 | $38 | |
J0897 |
Injection, denosumab, 1 mg | 1,981 | 21 | $23 | |
J1745 |
Injection, infliximab, excludes biosimilar, 10 mg | 1,410 | 11 | $30 | |
99213 |
Established patient office or other outpatient visit, 20-29 minutes | 335 | 208 | $87 | |
96413 |
Administration of chemotherapy into vein, 1 hour or less | 127 | 32 | $117 | |
96365 |
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 119 | 38 | $60 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 100 | 84 | $123 | |
76881 |
Complete ultrasound scan of joint | 86 | 43 | $15 | |
J3489 |
Injection, zoledronic acid, 1 mg | 80 | 16 | $9 |
In context: peer comparison
Among 148 peers in Cincinnati Internal Medicine Physician, average services per provider: 108. This provider delivers 125× the peer median.Open Payments
Industry payments received
All-time total
$555
Transactions
32
Manufacturers
13
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Abbvie INC. | 15 | $178.65 | |
| Amgen INC. | 2 | $50.42 | |
| Pfizer INC. | 1 | $48.39 | |
| Ucb, INC. | 2 | $39.76 | |
| Novartis Pharmaceuticals Corporation | 2 | $37.92 | |
| Actelion Pharmaceuticals US, INC. | 2 | $34.03 | |
| Organon LLC | 2 | $31.43 | |
| Janssen Biotech, INC. | 1 | $29.20 | |
| E.R. Squibb & Sons, L.L.C. | 1 | $28.14 | |
| DePuy Synthes Sales INC. | 1 | $24.35 | |
| Mallinckrodt Hospital Products INC. | 1 | $19.98 | |
| Lilly USA, LLC | 1 | $17.64 | |
| Genentech USA, INC. | 1 | $15.12 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
1,402
Patients
446
Total drug cost
$786,254
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Methotrexate (Methotrexate Sodium) | Brand | 318 | 91 | $14,279 |
| Hydroxychloroquine Sulfate | Generic | 312 | 103 | $35,375 |
| Prednisone | Generic | 272 | 108 | $3,117 |
| Gabapentin | Generic | 68 | 23 | $1,695 |
| Sulfasalazine | Generic | 60 | 22 | $2,427 |
| Allopurinol | Generic | 58 | 15 | $1,045 |
| Humira(Cf) Pen (Adalimumab) | Brand | 51 | 0 | $483,365 |
| Alendronate Sodium | Generic | 38 | 17 | $483 |
| Duloxetine Hcl | Generic | 38 | 17 | $2,860 |
| Leflunomide | Generic | 36 | 12 | $10,555 |
Hospital affiliations
Frequently asked questions
What is Dr. Greg Mott's medical specialty?
Dr. Greg Mott practices Internal Medicine Physician in Cincinnati, OH.
Where does Dr. Greg Mott practice?
Dr. Greg Mott practices at 234 Goodman St., Ml 0781, Cincinnati, OH 45219. Office phone: 5135844505.
What is Dr. Greg Mott's NPI?
Dr. Greg Mott's National Provider Identifier (NPI) is 1093101750, issued by NPPES.
Does Dr. Greg Mott accept Medicare assignment?
Yes. Dr. Greg Mott accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Greg Mott commonly perform?
Top Medicare-reported procedures in 2023: Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (HCPCS J0129); Injection, infliximab-abda, biosimilar, (renflexis), 10 mg (HCPCS Q5104); Injection, denosumab, 1 mg (HCPCS J0897). Source: CMS Medicare Physician & Other Practitioners file.